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Multiple Model Evaluation Absent the Gold Standard
via Model Combination
Edwin S. Iversen, Jr., Giovanni Parmigiani and Sining Chen∗
Abstract
We describe a method for evaluating an ensemble of predictive models given a sam-
ple of observations comprising the model predictions and the outcome event measured
with error. Our formulation allows us to simultaneously estimate measurement error
parameters, true outcome — aka the gold standard — and a relative weighting of
the predictive scores. We describe conditions necessary to estimate the gold standard
and for these estimates to be calibrated and detail how our approach is related to,
but distinct from, standard model combination techniques. We apply our approach to
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data from a study to evaluate a collection of BRCA1/BRCA2 gene mutation predic-
tion scores. In this example, genotype is measured with error by one or more genetic
assays. We estimate true genotype for each individual in the dataset, operating char-
acteristics of the commonly used genotyping procedures and a relative weighting of
the scores. Finally, we compare the scores against the gold standard genotype and
find that Mendelian scores are, on average, the more refined and better calibrated of
those considered and that the comparison is sensitive to measurement error in the gold
standard.
Keywords: Model Evaluation; Model Combination; Measurement Error; Breast
Cancer Susceptibility Genes; Bayesian Analysis.
1 Introduction
Numerous medical conditions can be diagnosed only to a level of uncertainty via one or more
tests, be they diagnostic, biomarker–based or probabilistic. In addition to the obvious clinical
implications, this complicates evaluation of competing diagnostic tools because the true
condition of patients in the evaluation sample, sometimes referred to as the ’gold standard’
for comparison, is not known (Hui and Walter 1980). In what follows, we describe and
apply a method for evaluating an ensemble of prognostic models given a sample on which
those models have been evaluated and for which the outcome event is measured with error.
This work is inspired by a multi–center validation study of BRCA1/2 mutation carrier
probability models carried out within the Cancer Genetics Network (CGN). These models
are routinely used in high risk cancer clinics as a counseling tool prior to formal genetic
testing, but their predictions may be inconsistent. For each study participant, the CGN
validation data set contains genetic test results at BRCA1 and BRCA2, BRCA1/2 carrier
scores, denoted S1, · · · , SM , calculated for M = 9 models and a small number of family
history summaries. Section 3 provides a complete listing of fields collected in context of the
2
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CGN validation study. Each carrier probability score Sm is a function of the individual’s
family history and, with a few exceptions, each is an estimate of Pr(G | F) where F denotes
the individual’s family history of breast and ovarian cancer and G is an indicator of whether
or not the individual carries a disease associated mutation at BRCA1 or BRCA2. A subset
of these scores was built by modeling test result T as a function of F. In principle, these
scores could be compared to those built explicitly to predict G by multiplying the latter
class by test sensitivity thereby putting them on the same — but clinically less relevant —
footing, given test specificity is 1. That the test used to train the former class of scores is
usually not the same used in clinic further complicates this approach.
It is often the case that measurement error in the gold standard is ignored in evaluations of
competing prognostic models. Indeed, in an accompanying report (Parmigiani et al. 2007)
we compare the various BRCA1/2 carrier scores using assay result as the gold standard.
This is also the approach taken in Barcenas et al. 2006. Here we demonstrate that such
a comparison can be sensitive to this practice and provide the foundation for a less biased
evaluation.
2 Modeling Approach
2.1 The Sampling Model
Most CGN study subjects were from centers that collected, or ascertained, them on the basis
of the extent of disease present in their family histories. We account for this in our model
by conditioning on family history, F, through the carrier probability scores, each of which
is a function of F (in fact, it is not uncommon for recruitment of individuals to studies of
women at high genetic risk of breast cancer to explicitly depend on one or more of the scores
under evaluation). In particular, we use a retrospective model (Kraft and Thomas 2000) for
genetic test results at BRCA1 and BRCA2, denoted T1 and T2 respectively, given carrier
3
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probability scores S1, · · · SM , covariates X and model parameters θ. The parameter vector θ
is comprised of test sensitivity and mutation prevalence parameters and parameters relating
carrier probabilities to genotype. The model is also conditional on P1 and P2, the BRCA1
and BRCA2 test protocols employed.
The conditional sampling model we utilize relates carrier probability model scores to test
results via latent variables for genotype. In particular, we write




Pr(T1, T2 |G1, G2, P1, P2, β1, β2)Pr(G1 |G,X, γ1) Pr(G |S1 · · ·SM ,X, γ2). (1)
We code test result Tg = 1 if the individual tests positive for a disease associated mutation
at BRCAg, g ∈ {1, 2}; Tg = 0, otherwise. Similarly, we code genotype Gg = 1 if the
individual truly carries a disease associated mutation at BRCAg; Gg = 0, otherwise. We
define G = G1 ∨ G2. The operating characteristics of the genetic tests are imperfect.
While it is well established that they are specific (Iversen Jr. et al. 1999; Myriad Genetics
2003), their sensitivities vary and may be significantly less than one. We introduce gene–
and test–modality–specific sensitivity parameters, βg = (βg,1 · · · βg,Ng), for test protocols
Pg ∈ {1 · · · Ng}. We ignore the extremely rare possibility that a tested individual may
harbor disease-associated mutations at both genes ((G1, G2) = (1, 1)). Further assumptions
made in Equation 1 are given below.
Test Results Given Bivariate Genotype. We assume that test results are indepen-
dent of X and the scores given genotype and that the two tests are conditionally independent
given genotype and test protocols, yielding
Pr(T1, T2 | G1, G2, P1, P2, β1, β2) = Pr(T1 | G1, P1, β1) Pr(T2 | G2, P2, β2), (2)
Each factor Pr(Tg | Gg, Pg, βg) in this expression is Bernoulli with modality–specific success
probability βg,Pg given Gg = 1 and a point mass at {Tg = 0} otherwise. This expression is
4
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easily adapted to tests with specificity less than 1.
Bivariate Given Univariate Genotype. The second factor in Equation 1 relates
joint BRCA1, BRCA2 genotype (G1, G2) to combined genotype, G, and covariates. Here, we
assume that the likelihood of BRCA1 genotype G1 is Bernoulli and conditionally independent
of the carrier probability scores given G = 1 and X, where X includes variables that modify
prevalence of BRCA1 mutations or distinguish the BRCA1/2 familial phenotypes. These are
related to G1 through a logistic regression on the subset of the sample with G = 1. When
G = 0, this component places a point mass at (G1, G2) = (0, 0).
Univariate Genotype Given Scores. While some of the scores make joint BRCA1
and BRCA2 predictions, the CGN study only collected combined predictions. Thus we
relate the carrier probability scores and covariates in X to combined genotype, G, through a
regression model of the form Pr(G | S1, · · · , SM ,X, γ2) where γ2 is the vector of regression
coefficients. This component is central to the analysis: it relates the carrier scores to the
gold standard variable G. One way of thinking about it is as another score of the form
Pr(G | F), one that assumes that G is conditionally independent of F given the various
scores S1(F), · · · , SM(F). It serves as, and could function in the role of, a composite carrier
probability score.
We consider two formulations for this regression model: a multiplicative model




where f(·) defines a transformation of the scores; and an additive model
pij = γ2,0 +
M∑
m=1
γ2,m Sj,m subject to
M∑
m=0
γ2,m = 1 and γ2,m > 0 ∀ m. (4)
Identifiability. In both formulations, identifiability of γ2, β1 and β2 is guaranteed given
all but exceptional arrangements of the data and a collection of non–trivial scores. Gold
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standard genotypes G are estimable when γ2, β1 and β2 are identified. To see this, note that
the likelihood in Equation 1 marginalized over G1 and G2 is a product of individual–specific
multinomial terms with success probabilities (β1ρjpij, β2(1−ρj)pij, 1−β1ρjpij−β2(1−ρj)pij)
when there is one test modality employed and where ρj denotes Pr(G1,j |Gj = 1,Xj, γ1) and
j indexes the individual. Note that β1 or β2 always multiplies pij. Hence multiplying β1 and
β2 and dividing pij by the same constant 0 < c < 1 yields the same value of the likelihood.
In the additive formulation, this corresponds to dividing γ2 by that constant. However,
the constraint that it sums to 1 prevents this and thus its parameters are identifiable. In
the multiplicative formulation, identifiability is guaranteed if the design matrix S is of full
rank and no components of γ∗2 are uniquely determined by the system of equations S
Tγ2
∗ =
logit(c · expit(STγ2)) for 0 < c < 1 and arbitrary γ2. The same applies in the case where
there are multiple assays.
Calibration. The multiplicative model is a prospective model for G given the S’s.
It corresponds to a joint formulation Pr(G,S1, · · · , SM | parameters) in which the Sm’s are
conditionally independent beta distributed random variables given G and in which G is
Bernoulli(pi). In the prospective version, elements of γ2 are simple functions of pi and the beta
distribution parameters. While interpretation of the joint model’s parameters is complicated
in cases where the implied conditional independence assumption is not tenable, as is the
case in the analysis described below, inference for the latent genotypes is not necessarily
compromised. For our purposes, all that is necessary is for the prospective model to be
calibrated (a score S is calibrated for G if Pr(G = 1 |S = s) = s). This would be achieved
if, for example, any one score entering the retrospective model, say Sm, is calibrated forG and
γ2,m = 1 and γ2,m′ = 0 for all m
′ 6= m. In contrast, the additive model has a corresponding
joint formulation under certain restrictions on the coefficients that are outlined in Genest
and Schervish 1985. It is calibrated if, among other scenarios, the intercept and coefficients
associated with uncalibrated scores are zero. In our analysis we set the intercept to zero.
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An alternate approach to Equation 1 is to model the joint distribution of test results
and scores, i.e. Pr(S1, · · · , SM , T1, T2 | θ). This model is related to that described by Hui
and Walter 1980 who write a joint likelihood for an arbitrary number of binary tests with
unknown error rates for a sample that can be divided into subpopulations with unknown, but
different, disease prevalences (see also Walter and Irwig 1988). One shortcoming of taking
this approach in the current context is that it ignores the differential modes of ascertain-
ment employed across and sometimes within the various centers and could result in biased
inferences. The retrospective likelihood is ‘ascertainment assumption free’ to the extent that
ascertainment of subjects in the data set depends on family history through a function of
the scores. Indeed, in many settings this is exactly the case.
2.2 Relation to Model Combination
The purpose of the models described in Equations 3 and 4 is to generate a “third party”
consensus for the latent genotypes that does not a priori favor any score or subset of scores;
a byproduct is to identify a composite carrier probability model. We view this modeling as
a device for combining expert (statistical) opinion across M experts vis-a-vis the unknown
genotype of test–negative probands. When we choose the logit transformation for f in Equa-
tion 3 we define a logarithmic opinion pool (Genest and Zidek 1986) of the form described
by Bordley 1982. This approach represents a quasi–Bayesian combination of evidence –
‘quasi’ in the sense that prior odds, specified as a function of γ2,0, are a mathematical con-
struct not elicited prior to assembling the expert evidence (French 1985; Genest and Zidek
1986; Dawid et al. 1995). The model of Equation 4 defines a linear opinion pool.
Our procedure departs from the typical problem of combining probabilities in two im-
portant respects. First, typically there is a single defined event (or event space) of interest.
In the current setting, we have a series of events, each corresponding to the genotype of one
of the probands. A fixed set of M automated experts proffer their opinions, in the form
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of scores, on each individual’s genotype. The parameters γ2,1 · · · γ2,M define the relative
weights accorded the scores. These weights are taken to be the same from event to event
(i.e. across probands). Second, we observe the events of interest, albeit measured with error.
This allows us to estimate the weights.
This approach, a regression based combination of model forecasts, is one that has been
used to improve meteorological (Kharin and Zwiers 2002; Gel et al. 2004; Gneiting et al.
2005) and econometric (Makridakis and Winkler 1983) predictions. In the meteorological
literature, forecasts derived from collections of predictive models, termed multi-model en-
sembles, are combined using either deterministic weights (Thompson 1977) or empirically
derived weights (Fraedrich and Smith 1989; Krishnamurti et al. 1999; Kharin and Zwiers
2002), for example from a regression of forecasts given a set of observations of the event.
This procedure corresponds to a linear opinion pool with empirically determined weights.
While the models being combined may be similar, e.g. reflecting like–minded analyses of
nonidentical data sets in the sense of (Dawid et al. 1995), there is evidence that there is
strength in combining predictions based on very dissimilar models (Makridakis and Winkler
1983; French 1995) that derives from accounting for model uncertainty. There is a growing
literature on formal Bayesian methods for incorporating model uncertainty through model
averaging (Clyde and George 2004). Bayesian model averaging combines models in weighted
averages where the weights are determined by the marginal likelihood of the data associated
with each model. This approach arises in the so called M–closed setting, where the true
model is assumed to be included in the average (Key et al. 1999). In the M–open setting,
where this is not the case, model forecasts may be optimally combined via a weighted mul-
tivariate regression of observed forecasted events on out–of–sample forecasts, resulting in an




3.1 CGN Data Set
The Cancer Genetics Network’s (CGN) Validation of BRCA1&2 Carrier Probability Models
study assembled a multi–center database of carrier probability scores, family history sum-
maries and other data on BRCA1/2 tested individuals for use in evaluating performance
of those models. Data were provided by eleven centers. Center by center summaries are
provided in Table 1. With the exception of three, all provided data on high risk families
recruited in counseling clinics. The cases from Seattle were selected from a population–based
series of breast cancer cases diagnosed before age 45 either on the basis of early age at di-
agnosis (< 35) or incidence of breast cancer in a first–degree family member. The cases
from Baylor comprise a cohort from a community–based study who underwent testing for
the 185delAG BRCA1 Ashkenazi Jewish founder mutation and provided a complete family
history of cancer. Cases from UC Irvine are the first 803 participants in a study of all breast
cancer cases diagnosed in Orange County, California during the period 3/1/94 to 2/28/95.
Centers carried out the various model calculations themselves and assembled their datasets
using CaGene (Euhus et al. 2002), a software package used in genetic counseling; in most
cases, we did not have access to the raw family data.
A variety of genetic testing strategies were employed by the centers participating in this
study. At some centers, multiple assays were implemented serially to improve sensitivity of
the overall testing procedure. The various assays and their combinations are specific and
their false positive rates can be assumed to be negligible, but their sensitivities vary. Table
1 summarizes the assays employed by the participating centers.
The project evaluated nine BRCA1/2 carrier probability models. Four are empirical
models built by modeling test data as a function of various family history summaries. They
9
Hosted by The Berkeley Electronic Press
Center Population Number Number Number BRCA1 BRCA2
Tested for Tested for Tested for Testing Testing
BRCA1&2 BRCA1 Only BRCA2 Only Method Method
Baylor AJa volunteers 0 282 0 AJ Sequencing NAd
Duke High risk 275 0 0 SSCP, CSGE SSCP, CSGE
Georgetown High risk 230 11 1 Seqc, 0ncormed, AJ Seq ASO
Johns Hopkins High risk 102 3 0 Seq, AJ Sequencing Seq, AJ Seq
Penn High risk 472 159 45 CSGE, Seq, AJ Seq, SSCP Seq, CSGE, AJ Seq
Seattle High riskb 384 199 0 SSCP SSCP
MD Anderson High risk 115 2 0 Sequencing Sequencing
UTSW High risk 115 6 0 Sequencing Sequencing
UC Irvine Popn–Based 803 0 0 ASO, AJ Seq AJ ASO, Unknown
Utah High risk 61 0 0 Sequencing Sequencing
City of Hope High risk 76 1 0 Sequencing, AJ Seq Seq, AJ Seq
Table 1: Centers participating in the CGN validation study, their source population, sample contribution and testing
methods employed. The high risk population refers to individuals presenting to clinics or involved in research studies for reason
of a family history of breast and ovarian cancer. Population based samples are tied via a known sampling scheme to a population
cancer registry. Volunteers to the Baylor study responded to an advertisement. Assays used in testing for disease associated




bHigh risk subsample of population–based series
are the Myriad (www.myriad.com) model (Frank et al. 1998; Frank et al. 2002) for predicting
results of testing at BRCA1 and BRCA2; the NCI model (Hartge et al. 1999) for testing
positive for one of the three Ashkenazi Jewish BRCA1/2 founder mutations; the University
of Pennsylvania model (Couch et al. 1997) for predicting whether one or more individuals in
a family will test positive for a mutation at BRCA1, modified to predict for the individual in
the family seeking testing (the “counseland”); and the Finnish model (Vahteristo et al. 2001)
for predicting results of a test for a BRCA1 or BRCA2. The three variants of BRCAPRO
(Berry et al. 1997; Parmigiani et al. 1998) and the Yale model (Claus et al. 1990; Claus
et al. 1991) are Mendelian models, i.e. models for family history data that formally account
for the underlying Mendelian genetic model using a formal likelihood based on that described
in Elston and Stewart 1971. BRCAPRO predicts the joint mutation status at BRCA1 and
BRCA2, while the Yale model predicts that of a single autosomal dominant disease gene
predisposing to breast and ovarian cancer (effectively combining BRCA1 and BRCA2).
The empirical and Mendelian models predict different quantities. The former predict the
likelihood of testing positive to a genetic test with sensitivity and specificity equal to that
10
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used the model building data set while the latter predict an individual’s actual genotype.
The remaining model, Family History Assessment Tool (FHAT) (Gilpin et al. 2000), is
a quantitative ’expert–based’ score developed to assist clinicians in identifying appropriate
candidates for counseling. It is derived from responses to a family history questionnaire and
is measured on a 45 point scale; we rescaled it to range between 0 and 1. More detail on the
CGN study can be found in Parmigiani et al. 2007.
3.2 Model Specification
The model in Equation 1 is factored into three components. In what follows, we discuss
specification of each, including our choice of priors.
Test Results Given Bivariate Genotype. Equation 2 specifies the structure of this
component whose parameters are the sensitivities of the genetic testing procedures listed
in Table 1. We derived informative priors by conducting a meta–analysis of published
data (Geisler et al. 2001; Eng et al. 2001; Andrulis et al. 2002) in which we treated these
studies as independent trials and pooled their results. This analysis suggested a beta(73.5,
43.5) prior on sensitivity of SSCP and SSCP followed by ASO and a beta(27.5, 18.5) on
sensitivity of CSGE. The beta(3.27,0.39) prior on sensitivity for testing for BRCA1 185delAG
but not BRCA1 5382insC was based on the relative proportion of these mutations in the
Ashkenazi population as observed in Roa et al. 1996; Hartge et al. 1999. The remaining
testing modalities were accorded uniform priors on their sensitivities. In addition, we applied
to these priors a set of ordering constraints. For BRCA1, these reflected the beliefs that full
gene sequencing is more sensitive than any other assay, including selected search for an AJ
founder mutation by sequencing; that both sequencing strategies are more sensitive than
SSCP or CSGE; that sensitivity of sequencing or ASO for one AJ mutation is less sensitive
than sequencing or ASO for both; and that any assay is less sensitive alone than when used
in combination with any other. Similar constraints were applied to the assays employed for
11
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BRCA2. Individuals tested for mutations at only one of the two genes were treated as if
they had been tested using an assay with sensitivity zero for the untested gene.
We believe these studies to be of high quality and that incorporating data from them
improves the model. We explore the robustness of our analysis to these prior data in Sec-
tion 3.6, where we report on sensitivity of the latent genotypes, and of the comparison of
scores given those genotypes, to this prior.
Bivariate Given Univariate Genotype. The event that a mutation carrier’s muta-
tion is located at BRCA1 is modeled by a logistic regression on X. In the current analysis,
X includes only ethnicity. If the data had been available, we would also have included
summaries of family history that help to distinguish the BRCA1 and BRCA2 phenotypes.
However, without data on tumor markers, whose significance is only now becoming clear,
BRCA1 and BRCA2 carriers are difficult to distinguish from one another even given family
history data, and these data probably would not contribute much. The parameters most
sensitive to misspecification of this component will be the sensitivity parameters as mis-
specification will affect the model’s ability to discriminate whether likely false negatives are
truly BRCA1 or BRCA2 carriers. These are ancillary inferences, however; our interest is in
constructing an accurate estimate of the marginal genotype G — the relevant quantity for
clinical management and genetic testing decisions — and in understanding its relationship
to the scores. We placed diffuse independent 10 degree of freedom, mean zero Student–t
priors on the coefficients; the prior standard deviation was 100 for the intercept and 5 for
ethnicity.
Univariate Genotype Given Scores. This component is either a multiplicative (Equa-
tion 3) or additive (Equation 4) regression of latent genotype on the carrier probability
scores. We included dummy variables to indicate the subsets of observations to which the
NCI, Penn and Finnish scores apply to allow for the fact that not all models are universally
applicable. We include a term for each carrier score under evaluation. Three variants of the
12
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BRCAPRO model are included: its standard formulation, one calculated assuming 50% of
the standard formulation’s penetrance and one calculated assuming penetrances generated
by applying age–independent relative risks (AIRR) to the phenocopy rates of breast and
ovarian cancer. This is to allow for sensitivity of the Mendelian scores to assumed pene-
trance. In addition, we include indicator variables for a family history of prostate cancer,
colon cancer and endometrial cancer as tools for discovering new factors that might be used
to improve existing carrier probability models. Finally, we adjust for the counseland’s phe-
notype — the counseland’s age, whether she had breast cancer, bilateral breast cancer, or
ovarian cancer — and mode of data ascertainment (population–based or high–risk). Because
coefficients in the additive formulation are restricted to be positive, we include in the addi-
tive model indicators and scores for the complementary events. The model is constrained so
that a variable and its complement will never co–appear. Terms appearing in the genotype
model are listed in Table 2.
3.3 Out–of–Sample Evaluation of Genotype Model
In this and the next two subsections we focus on model choice and evaluation. Here we
evaluate the multiplicative (Equation 3) and additive (Equation 4) formulations. In the next
subsection we focus on specification of the genotype model’s linear predictor and estimation
of the gold standard. Finally, we utilize these estimates to compare the carrier scores.
Integrity of the evaluation and comparison of the scores depends on accuracy of the
imputed genotypes. In light of this, we evaluated out–of–sample predictive accuracy of the
additive and multiplicative formulations using the subset (n=640) of probands with family
history data who received full gene sequencing. Sensitivity of sequencing is high, on the
order of 0.9; specificity is effectively 1. For the purpose of this analysis, we ignored assay
error and equated test result with binary genotype, G. We randomly divided the dataset
into 100 subsets. For each subset, we fit both models to the remaining subsets and, under
13
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each model, calculated predictions for the left–out subset.
We judged the models on the basis of the overall accuracy, calibration and refinement
of their out–of–sample predictions. We found the additive formulation to be superior on
the basis of these criteria and in terms of interpretability. Using root mean squared error
(RMSE) as the measure of overall accuracy, we found the additive model to be more accurate
(RMSE=0.387) than the multiplicative model (RMSE=0.391). In both cases, we found the
bias to be negligible (-0.0031 for the additive predictions; -0.0005 for the multiplicative
predictions). Model calibration, a measure of reliability in repeated forecasts, quantifies
agreement between the forecast value and the frequency of the forecasted event as a function
of the forecast value (DeGroot and Fienberg 1983). We addressed calibration by comparing
the accuracy of the predictions within deciles of the predicted values. One–way analyses
of variance of the deviations given the factor ‘predictive decile’ suggest that the additive
predictions are better calibrated on the whole and suffer less from systematic deviations
from calibration: the model mean square for the additive predictions was 0.115 and the
residual mean square was 0.151; the associated quantities for the multiplicative model were
0.213 and 0.152. In these analyses, decile represents an ad hoc correction to calibration that
explains nearly twice as much deviation from calibration under the multiplicative than under
the additive model.
Model refinement is related to forecaster accuracy. In the case of a binary event, both
the constant forecast equal to the true prevalence of the event and the binary forecast that
is always correct are well calibrated; the latter is refined, the former is not (DeGroot and
Fienberg 1983). We report two measures of refinement: the receiver operating characteris-
tic (ROC) curve and the area under the curve (AUC), also termed the concordance index
(Harrell Jr et al. 1982). Figure 1 depicts ROC curves for the additive (left panel) and
multiplicative (right panel) predictions. To form a basis of comparison, each plot also in-
cludes curves for two hypothetical scores, one of which is perfectly calibrated and has the
14
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same marginal distribution as the predictions (heavy dashed line) while the other is com-
pletely uninformative (dashed diagonal). Note that the additive predictions substantially
overlap the associated hypothetical calibrated score while this is not true of the multiplica-
tive predictions. The area under the ROC curve is 0.757 for the additive and 0.762 for the
multiplicative predictions.
To calculate the perfectly calibrated reference curve, note that a score S is perfectly
calibrated for G if s = Pr(G = 1 |S = s). Let S¯ denote the sample mean of S and note that
Pr(S |G = 1) ' S/(nS¯) for S in {Si : i = 1, · · · , n} when Pr(S) is estimated by its empirical
distribution in the sample of interest; similarly, Pr(S |G = 0) ' (1 − S)/(n(1 − S¯)). The




{i:Si>s&Gi=1} Pr(Si |Gi)) as s varies
between 0 and 1.
Figure 1: ROC plots for the out–of–sample evaluation of the additive (left panel) and multiplicative (right panel) models.
The ROC curve plots the positive predictive value (PPV) against the negative predictive value (NPV) of a continuous score
as a function of a threshold that varies through the range of scores (here 0 to 1). Each plot depicts 3 ROC curves: the curve
associated with the predictions (solid line), the curve associated with a hypothetical perfectly calibrated curve with the same
marginal (heavy dashed line) and a hypothetical uninformative score (dash line on the diagonal).
































































































In the course of exploratory analysis using the multiplicative and additive formulations we
examined various additional explanatory variables, including transformations of the scores
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and a variety of summaries of extent of family history, for their ability to improve the
accuracy of the model for genotype given scores. None were found to add to the explanatory
ability of the models as originally formulated. We conclude that the additive model is more
accurate and better calibrated than the multiplicative model. For these reasons and the fact
that it is easier to interpret, we focus on the additive model in its original formulation. An
evaluation of scores in the subset of sequenced individuals using assay result as the standard
of comparison can be found in Parmigiani et al. 2007.
3.4 Model Fit & Estimation of Gold Standard
We fit the additive variant (Equation 4) of the model described by Equation 1 to the
full CGN dataset using a Markov chain Monte Carlo (MCMC) algorithm. We placed a
Dirichlet(1, · · · , 1) prior on γ2. Latent genotypes G1i and G2i were drawn from individual–
specific multinomial distributions; β1 and β2 were drawn from their full conditional distribu-
tions and γ1 was updated using an independence sampler (Tierney 1994) that achieved an
acceptance rate of 93%. Finally, we updated γ2 and the specification of the linear predictor
in Equation 4 using a reversible jump step. Three move types were employed: (1) update γ2
associated with the current model, (2) add an additional variable and (3) remove a variable.
Moves were constrained so that a variable would never enter the model with its complement.
We tested the code by removing the likelihood from the acceptance calculation and observed
that the MCMC estimate of the distribution over the number of regressors coincided with
its theoretical counterpart.
The chain was run for a lengthy burn–in period and one million subsequent iterations.
The chain was thinned to every 5th realization, leaving two hundred thousand draws for
inference. We employed a battery of convergence diagnostics implemented in the R package
CODA to evaluate the convergence of non–dimension–varying parameters. All passed the
Raftery and Lewis diagnostic (Raftery and Lewis 1996), the Heidelberger and Welch sta-
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Table 2: Estimates of the coefficients in the additive regression model associating latent binary BRCA1/2 genotype and the
various carrier scores, a set of family history summaries, and subset and population indicators. Coefficients were constrained to
be positive and sum to 1. Each variable was allowed to enter the model either as itself (x; columns 2-4) or as its complement
(1 − x; columns 5-7). Age was scaled to range between 0 and 1. Model specification was considered a random variable and
models were visited via a random walk. Estimates in the table are of posterior means (columns 2, 3, 5 and 6) and standard
deviations (columns 4 and 7) derived from the MCMC analysis. The second column provides estimates of the probability that
the associated variable is in the model. Columns 3 and 4 summarize the posterior on the coefficient averaging over models that
include the variable.
Variable “x” Complement of Variable “1-x”
Predictor Pr(Included) E(γ2,p|In) SD(γ2,p|In) Pr(Included) E(γ2,p|In) SD(γ2,p|In)
NCI Indicator 0.5425 0.0239 0.0131 0.0077 0.0030 0.0026
Penn Indicator 0.0374 0.0046 0.0038 0.0857 0.0111 0.0099
Finnish Indicator 0.0319 0.0044 0.0038 0.0858 0.0097 0.0085
High Risk Indicator 1.0000 0.1070 0.0158 0.0000 −−− −−−
BRCAPRO Model 0.9947 0.2518 0.0768 0.0002 0.0052 0.0045
BRCAPRO, 50% Penetrance 0.9999 0.3520 0.0793 0.0000 −−− −−−
BRCAPRO, AIRR 0.4394 0.0739 0.0578 0.0196 0.0042 0.0037
Yale Model 0.0850 0.0131 0.0123 0.0425 0.0050 0.0047
Myriad/Frank Model 0.4061 0.0614 0.0483 0.0198 0.0042 0.0035
NCI Model 0.1082 0.0164 0.0151 0.0345 0.0044 0.0040
Penn Model 0.4097 0.0644 0.0500 0.0186 0.0041 0.0040
FHAT Model 0.1559 0.0259 0.0242 0.0300 0.0049 0.0044
Finnish Model 0.9666 0.1691 0.0619 0.0012 0.0036 0.0034
Counseland First Breast Cancer 0.0337 0.0047 0.0043 0.0668 0.0074 0.0064
Counseland Breast Cancer Recur 0.0519 0.0081 0.0077 0.0528 0.0058 0.0050
Counseland Ovarian Cancer 0.1864 0.0212 0.0167 0.0298 0.0041 0.0040
Age, Scaled to [0,1] 0.0413 0.0060 0.0055 0.0756 0.0097 0.0088
(Scaled Age)2 0.0514 0.0077 0.0072 0.0623 0.0072 0.0066
Family History Prostate Cancer 0.0338 0.0053 0.0050 0.0671 0.0072 0.0057
Family History Colon Cancer 0.4726 0.0215 0.0121 0.0085 0.0030 0.0030
Family History Endometrial Cancer 0.1403 0.0168 0.0138 0.0250 0.0038 0.0037
tionarity and half–width tests (Heidelberger and Welch 1983) and the Geweke diagnostic
(Geweke 1992) with each diagnostic’s parameters set to their CODA default values.
Table 2 tabulates estimated posterior means (columns 2 and 3) and standard deviations
(column 4) of the coefficients in the genotype regression (i.e. components of γ2). The second
column provides estimates of the probability that the associated variable is in the model.
Columns 3 and 4 summarize the posterior on the coefficient averaging over visited models that
included the variable. Columns 5–7 provide the same data for each variable’s complement.
Of the indicator variables for subpopulations, only the NCI indicator (indicating Ashkenazi
Jewish ancestry) and ascertainment mode show evidence of a significant modifying effect.
BRCAPRO, its half–penetrance version and the Finnish score are included in virtually
all models. Together their coefficients sum to about 0.77 on average. The BRCAPRO
age–independent relative risk (AIRR), Myriad/Frank and Penn scores are each included in
about 40% of models. The average coefficients accorded each range between 0.06 and 0.075.
The Yale, NCI and FHAT scores are each included in fewer than 20% of models and, when
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included, none has a coefficient that exceeds 0.03 on average. No score is included in more
than 5% of models as its complement and when one is, its average coefficient is estimated
to be smaller than 0.01. Interpretation of the coefficients associated with the various scores
is complicated by the fact that they reflect multivariate corrections for correlations between
them (Genest and McConway 1990); that a score’s coefficient is small or not significant does
not imply that it is a poor performer. We address the relative merits of the various scores
in the next section.
With exception of ovarian cancer, the counseland phenotype variables, including age,
rarely enter the genotype model. The ovarian cancer variable appears in roughly 19% of
models and its average coefficient is estimated to be about 0.02. This suggests that the
ensemble of carrier probability scores adequately accounts for the counseland’s breast and
ovarian cancer phenotype and age. While there is evidence that prostate, colon and endome-
trial cancers are associated with BRCA1 or BRCA2 (Aretini et al. 2003; Edwards et al.
2003; Risch et al. 2001), the carrier probability scores under consideration do not explicitly
account for a family history of these cancers with the exception of FHAT which depends
on prostate cancer. Our results suggest that accounting for these cancer sites may improve
accuracy of the scores. In particular, a family history of colon cancer is included in about
half of all models and, when included, its coefficient averages about 0.022. Further, using the
realizations of the BRCA1 and BRCA2 genotype vectors as covariates in binary regressions
of the 3 family history indicators, we see evidence of an association between counseland’s
BRCA1 genotype and a family history of colon cancer (averaging over genotype realizations,
odds ratio = 1.51, p-value = 0.0007) and weak evidence of an association between BRCA1
and family history of endometerial cancer (average OR = 1.36, p = 0.11). This evidence is
indirect because the family history indicators do not take into account the number of affected
relatives, their relation to the counseland and their ages at diagnosis.
Table 3 tabulates a posteriori estimates of sensitivity for each genetic testing modality.
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Table 3: Estimated posterior means and standard deviations (SD) of test sensitivity for the various BRCA1 and BRCA2
testing procedures employed in the CGN validation dataset. Targeted mutation screening and assays for the Ashkenazi founder
mutations BRCA1 185delAG, BRCA1 5382insC and BRCA2 6174delT are gene–specific; the remaining are general procedures.
BRCA1 BRCA2
Testing Modality Mean SD. Mean SD
SSCP 0.52 0.043 0.55 0.05
Sequencing 0.93 0.038 0.92 0.04
ASO 0.44 0.125 0.77 0.14
Targeted Mutation Screening 0.87 0.075 — —
Sequencing for 185delAG & 5382insC 0.84 0.073 — —
Sequencing for 185delAG only 0.72 0.127 — —
Sequencing for 6174delT — — 0.84 0.07
CSGE 0.68 0.052 0.60 0.06
Sequencing, then Follow–up Test 0.95 0.044 0.96 0.03
Targeted Mutation Screening + Sequencing 0.96 0.030 0.96 0.03
SSCP + ASO 0.67 0.040 0.80 0.10
Other 0.93 0.056 0.92 0.07
Sensitivity of BRCA1 and BRCA2 testing modalities vary widely. In the case of BRCA1,
they range from 0.44 to 0.96; for BRCA2 this range is 0.55 to 0.96. Modalities that involve
gene sequencing are the most accurate. When used in isolation, SSCP, CSGE and ASO are
the least accurate. The targeted strategies (sequencing for a panel of known mutations or for
founder or family mutations) are intermediate to these extremes, but largely because they
rely on prior information such as ethnicity or knowledge that a specific variant was found in
a family member. Interestingly, with exception of ASO, methods applied to both BRCA1
and BRCA2 are estimated to have comparable sensitivities across genes. While it is possible
that imperfect sensitivity of these tests may result from an undetected ”BRCA3,” there is no
evidence that an additional major breast cancer gene exists, though some minor candidates
could contribute to the negatives (Lacroix et al. 2005).
3.5 Evaluation of Scores Against the Gold Standard
In what follows, we evaluate the carrier scores against the average over MCMC realizations of
the latent genotype vector. The measures we focus on address model calibration, refinement
and overall predictive performance.
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Calibration. Figure 2 presents calibration plots for the 9 carrier probability mod-
els. This figure depicts point estimates (diamonds) and 95% equal-tailed interval estimates
(vertical segments) of carrier frequencies at mean scores within deciles of score. Variation
reflected in the segments results from sampling variability and uncertainty in the carrier sta-
tus of test negative subjects. Note that there are fewer than ten categories in summaries of
the Myriad/Frank and NCI scores because of their discrete nature. In all cases, calibration
is for predicting BRCA1 or BRCA2 genotype among all individuals with the exception of
the Penn model, which is for BRCA1 carriers among individuals not testing positive for a
BRCA2 mutation, and the NCI model which is restricted to AJ subjects. In these plots, a
well–calibrated score would have bin means that follow the diagonal; significant departures
from this indicate systematic biases. Note that the FHAT score was not designed to be
calibrated and hence its plot should not be expected to be linear.
To provide a quantitative measure of departure from calibration, we calculated root
mean squared error (RMSE) for each score’s ability to predict genotype, G, and observed
test result, T = T1 ∨ T2. For each score, we calculated RMSE for the unadjusted score,
for the score corrected for an estimate of bias, RMSE(1), and for the score corrected for
decile–specific estimates of bias, RMSE(D). Summaries for each carrier score are calculated
using only data from the population to which the score pertains (for example, Ashkenazi
Jewish individuals for the NCI score). These data are presented in Table 4. RMSE(D)
serves as an ad hoc measure of calibration: the closer its value is to RMSE, the better the
calibration of the score. For example, the unadjusted NCI score has an RMSE for test result
of 0.372 while its adjusted (for D) RMSE is 0.356. Of this difference, most is due to a global
downward bias: RMSE(1) is 0.360. In contrast, correcting BRCAPRO for D reduces its
RMSE for genotype from 0.348 to 0.323 with most of this difference due to a correction for
mis–calibration.
Overall Accuracy. Root mean–squared error (RMSE) and bias provide measures of
20
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Figure 2: Calibration plots for the 9 carrier probability models. For each model, subjects are divided into deciles bins
according to their carrier score. The proportion of carriers in each bin is indicated by a circle (mean) and a vertical segment
(95% interval). Variation reflected in the segments results from sampling variability and uncertainty in the carrier status of
test negative subjects. In all cases, calibration is for joint BRCA1 and BRCA2 genotype among all individuals with exception
of the Penn model, which is for BRCA1 carriers among individuals not testing positive for a BRCA2 mutation, and the NCI
model which is for a BRCA1 or BRCA2 founder mutation among AJ subjects.
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overall predictive performance. Estimates of these quantities are presented in Table 4 both
for predicting genotype and test result. Across subjects, BRCAPRO and its variants have the
lowest RMSE and bias for predicting genotype. In addition, it has the highest concordance
index (AUC) against both genotype and test result. The score labeled “Prevalence” corre-
sponds to using the empirical prevalence of mutation (columns 2–6) or test result (columns
7–11) as the score assigned to all individuals. This score is constant, hence unrefined. It
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Table 4: Accuracy, calibration and refinement for each score’s ability to predict genotype, G, (columns 1 – 5) and test
result, T = T1 ∨ T2, (columns 6 – 10) among all study subjects. The columns headed RMSE(1) and RMSE(D) are described
in the text. AUC is area under the ROC curve. Note that summaries for a carrier score are calculated using only data from the
population to which the score pertains (for example, Ashkenazi Jewish individuals for the NCI score). Note: (†) “Prevalence”
corresponds to using the empirical prevalence of mutation (columns 2–6) or test result (columns 7–11) as the score assigned to
all individuals in the highlighted subset; (‡) estimated prevalence can be found in the ’Bias’ column; bias is zero when using
the fixed prevalence of mutation as a score.
Predicting Genotype Predicting Test Result
Carrier Score Bias RMSE RMSE(1) RMSE(D) AUC Bias RMSE RMSE(1) RMSE(D) AUC
BRCAPRO 0.014 0.348 0.348 0.323 0.838 0.061 0.352 0.346 0.310 0.830
BRCAPRO, 50% -0.078 0.342 0.333 0.326 0.825 -0.031 0.320 0.319 0.307 0.817
BRCAPRO, AIRR -0.007 0.348 0.348 0.333 0.830 0.040 0.344 0.342 0.312 0.823
Yale -0.021 0.384 0.384 0.361 0.736 0.026 0.376 0.375 0.335 0.716
Myriad/Frank -0.054 0.354 0.350 0.346 0.764 -0.007 0.317 0.317 0.316 0.763
NCI -0.138 0.412 0.388 0.381 0.626 -0.097 0.372 0.360 0.356 0.621
Penn Model -0.072 0.377 0.370 0.367 0.736 -0.019 0.338 0.337 0.332 0.744
FHAT -0.057 0.360 0.355 0.341 0.796 -0.010 0.322 0.322 0.317 0.785
Finnish -0.072 0.379 0.372 0.369 0.767 -0.017 0.345 0.344 0.339 0.768
Prevalence† 0.191 ‡ 0.393 — — — 0.144 ‡ 0.351 — — —
is also unbiased; in the bias columns for this “score” we report the empirical prevalence of
mutation carriers (column 2) and of test positive subjects (column 7).
Were the comparisons to be made using test result as the gold standard, the Myr-
iad/Frank model, the half–penetrance variant of BRCAPRO and the FHAT model would
have appeared superior on basis of RMSE. This highlights that fact that comparison of the
scores is sensitive to the choice of gold standard. While multiplying the Mendelian predic-
tions by test sensitivity would likely improve their bias and RMSE for predicting test result,
we chose not to make this adjustment as test result is not the clinically relevant quantity.
Carrier probability scores are often employed for a specific purpose (e.g. genetic coun-
seling) in a particular setting or population (e.g. high–risk clinic), hence it is of interest to
evaluate the scores accordingly. The two primary population distinctions we choose to focus
on are high–risk versus population–based ascertainment and subjects with versus without
Ashkenazi Jewish heritage. A comparison of the scores against genotype in these popula-
tions is presented in panels (a) through (d) of Table 5. Note that using an empirical estimate
of prevalence as the score among population–based cases is better calibrated for mutation
status than five of the scores under investigation.
The subject’s cancer history is the single most important input to each of the carrier
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Table 5: Summaries related to the over all accuracy, calibration and refinement of the various carrier probability models as
displayed in Table 4. Each performance summary was calculated and is displayed for (a) high risk subjects only, (b) population–
based subjects only, (c) Ashkenazi Jewish Subjects only and (d) non–Ashkenazi Jewish subjects only. (e) cancer–free subjects,
(f) subjects affected with breast cancer only, (g) subjects affected with ovarian cancer only and (h) subjects affected with both
breast and ovarian cancer. Note: (†) the score named “Prevalence” corresponds to using the empirical prevalence of mutation
as the score assigned to all individuals in the highlighted subset; (‡) estimated prevalence can be found in the ’Bias’ column.
Bias is zero when using the fixed prevalence of mutation as a score.
Carrier Score Bias RMSE RMSE(1) RMSE(D) AUC Bias RMSE RMSE(1) RMSE(D) AUC
(a) High Risk Subjects (b) Population–Based Subjects
BRCAPRO 0.008 0.431 0.430 0.406 0.770 0.020 0.239 0.238 0.215 0.842
BRCAPRO, 50% -0.136 0.432 0.410 0.402 0.761 -0.019 0.216 0.215 0.214 0.799
BRCAPRO, AIRR -0.022 0.433 0.433 0.412 0.756 0.009 0.233 0.233 0.217 0.838
Yale -0.060 0.483 0.479 0.441 0.651 0.018 0.249 0.248 0.224 0.751
Myriad/Frank -0.135 0.449 0.428 0.426 0.692 0.027 0.220 0.218 0.218 0.788
NCI -0.229 0.511 0.457 0.452 0.538 -0.030 0.245 0.243 0.241 0.553
Penn Model -0.140 0.454 0.432 0.428 0.689 0.011 0.252 0.252 0.246 0.740
FHAT -0.142 0.457 0.434 0.422 0.718 0.028 0.223 0.221 0.217 0.827
Finnish -0.133 0.450 0.430 0.423 0.728 0.010 0.256 0.256 0.251 0.776
Prevalence† 0.321 ‡ 0.467 — — — 0.061 ‡ 0.238 — — —
(c) Ashkenazi Jewish Subjects (d) Non–Ashkenazi Jewish Subjects
BRCAPRO 0.081 0.396 0.387 0.356 0.809 -0.007 0.333 0.333 0.319 0.846
BRCAPRO, 50% -0.141 0.394 0.368 0.353 0.778 -0.059 0.325 0.319 0.314 0.846
BRCAPRO, AIRR 0.054 0.390 0.387 0.360 0.796 -0.025 0.334 0.333 0.321 0.839
Yale -0.105 0.405 0.391 0.379 0.673 0.004 0.378 0.378 0.349 0.762
Myriad/Frank -0.056 0.372 0.367 0.362 0.719 -0.053 0.348 0.344 0.339 0.758
NCI -0.138 0.412 0.388 0.381 0.626 — — — — —
Penn Model -0.044 0.392 0.390 0.387 0.737 -0.079 0.373 0.365 0.361 0.728
FHAT -0.109 0.394 0.378 0.361 0.776 -0.042 0.348 0.346 0.331 0.814
Finnish -0.164 0.429 0.396 0.389 0.729 -0.048 0.365 0.362 0.358 0.787
Prevalence† 0.214 ‡ 0.410 — — — 0.184 ‡ 0.387 — — —
(e) Unaffected Subjects (f) Breast Cancer Affected Subjects
BRCAPRO -0.040 0.288 0.286 0.284 0.730 0.041 0.371 0.369 0.340 0.834
BRCAPRO, 50% -0.079 0.299 0.289 0.281 0.682 -0.069 0.353 0.346 0.338 0.823
BRCAPRO, AIRR -0.042 0.292 0.289 0.287 0.725 0.009 0.369 0.369 0.347 0.822
Yale -0.069 0.304 0.296 0.293 0.583 0.031 0.400 0.399 0.364 0.766
Myriad/Frank -0.033 0.295 0.293 0.287 0.693 -0.062 0.374 0.369 0.365 0.721
NCI -0.087 0.321 0.309 0.306 0.401 -0.158 0.463 0.435 0.431 0.554
Penn Model -0.057 0.323 0.318 0.316 0.754 -0.077 0.385 0.377 0.374 0.696
FHAT -0.029 0.288 0.286 0.283 0.706 -0.056 0.375 0.371 0.359 0.771
Finnish -0.081 0.331 0.321 0.316 0.785 -0.068 0.386 0.380 0.376 0.730
Prevalence† 0.105 ‡ 0.306 — — — 0.205 ‡† 0.404 — — —
(g) Ovarian Cancer Affected Subjects (h) Breast and Ovarian Cancer Affected Subjects
BRCAPRO -0.035 0.354 0.352 0.336 0.880 0.049 0.357 0.353 0.325 0.875
BRCAPRO, 50% -0.135 0.385 0.360 0.338 0.844 -0.125 0.401 0.380 0.348 0.874
BRCAPRO, AIRR -0.036 0.358 0.356 0.340 0.873 0.066 0.357 0.350 0.334 0.865
Yale -0.232 0.472 0.411 0.371 0.572 -0.260 0.508 0.435 0.375 0.837
Myriad/Frank -0.025 0.358 0.357 0.327 0.839 -0.155 0.424 0.394 0.370 0.791
NCI -0.337 0.600 0.495 0.470 0.430 -0.629 0.719 0.343 0.170 0.873
Penn Model -0.076 0.463 0.456 0.430 0.640 -0.043 0.410 0.407 0.373 0.784
FHAT -0.083 0.397 0.388 0.348 0.824 -0.345 0.546 0.423 0.367 0.828
Finnish -0.057 0.412 0.407 0.365 0.822 -0.134 0.436 0.414 0.361 0.827
Prevalence† 0.260 ‡ 0.437 — — — 0.651 ‡ 0.474 — — —
scores under consideration, hence it is of interest to evaluate sensitivity of the scores to this
history. Panels (e) through (h) of Table 5 compare the scores when the sample is stratified
by prior history of breast and ovarian cancer. We estimate that, on average, each of the
carrier scores underestimates the probability of a mutation among subjects with no history
of breast or ovarian cancer and among subjects with only an ovarian cancer history. In all
23
Hosted by The Berkeley Electronic Press
strata, a BRCAPRO variant is the most calibrated score.
Refinement. Figure 3 plots ROC curves for the various carrier probability scores. In
all cases these curves are for predicting genotype. The three BRCAPRO variants dominate
this plot and are followed by the FHAT and Myriad/Frank scores.




























Figure 3: Receiver operating characteristic (ROC) curves for the various carrier probability
models predicting binary genotype (presence or absence of a disease associated mutation at
BRCA1 or BRCA2). By this measure, BRCAPRO and its variants are the most refined
scores. Estimates of area under the curve (AUC) are presented in Table 4.
3.6 Sensitivity to the Prior
We carried out a parallel analysis with unconstrained, independent uniform priors on the
test sensitivity parameters as a check to the robustness of the model. The remaining priors
in the model, which were chosen to be minimally informative, were left unchanged. We
compared the average value of the latent BRCA1 and BRCA2 genotypes in the subset of
test–negative individuals under the two models and found them to be highly correlated: we
calculated this correlation to be 0.87 for the gold standard BRCA1 genotype and 0.79 for
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the gold standard BRCA2 genotype. Further, 87% of the averaged latent BRCA1 genotypes
under the two priors were within 0.05 of one another; for BRCA2 this figure was 89%. Given
this level of concordance, it is not surprising that the comparison of scores was highly robust
to the choice of prior: correlations between the estimates in columns 1–5 of Table 4 and their
counterparts estimated under the model with the uninformative prior on assay sensitivities,
presented in Table 6 all exceeded 0.99.
Table 6: Main results under alternative prior on assay sensitivity parameters: accuracy, calibration and refinement for
each score’s ability to predict genotype, G, among all study subjects calculated with independent uniform priors on the assay
sensitivity parameters. Compare with columns 1–5 of Table 4. Note that summaries for a carrier score are calculated using
only data from the population to which the score pertains (for example, Ashkenazi Jewish individuals for the NCI score).
Carrier Score Bias RMSE RMSE(1) RMSE(D) AUC
BRCAPRO -0.001 0.351 0.350 0.335 0.839
BRCAPRO, 50% 0.091 0.353 0.341 0.334 0.830
BRCAPRO, AIRR 0.020 0.353 0.352 0.340 0.830
Yale 0.034 0.390 0.388 0.368 0.754
Myriad/Frank 0.067 0.365 0.358 0.354 0.760
NCI 0.156 0.428 0.398 0.389 0.627
Penn Model 0.086 0.388 0.378 0.375 0.735
FHAT 0.070 0.371 0.364 0.349 0.792
Finnish 0.086 0.389 0.379 0.376 0.766
4 Discussion
In this paper, we have presented and applied a method for evaluating an ensemble of pre-
dictive models for genotype given a sample on which those models have been evaluated and
for which the outcome event is measured with error. Its formulation allows for simultane-
ous estimation of the measurement error parameters, latent genotype and parameters that
represent a relative multivariate weighting of the carrier scores. We have found that the
relative performance of the scores is affected by whether genotype or an imperfect test of
genotype is used in the evaluation. The Mendelian models are more accurate for predicting
genotype, the quantity of interest. When assay error is ignored, performance evaluations
are biased in favor of the empirical models. Our results are broadly consistent with those of
(Barcenas et al. 2006) who compare a set of carrier models overlapping those studied here
on a set of 472 sequenced individuals. They found that the Myriad model was comparable
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to the Mendelian models BRCAPRO and BOADICEA on basis of AUC and that all per-
formed better than the Penn model. We found that the Myriad model does less well than
the Mendelian models for predicting both genotype and test result using this metric.
Because the entire analysis is conditional on the scores which are summaries of family
history, it is robust to biases resulting from ascertainment to the extent these scores capture
the features of family history upon which decisions to sample were made. Further, while
it is possible that a score’s performance may be overstated when the score is evaluated on
basis of an estimated genotype that depends in part on the score, the parameterization of
the regression of latent genotype on scores is designed not to favor any score or subset of
scores a priori.
While the application we describe is specific to the setting of evaluating quantitative car-
rier scores for BRCA1 and BRCA2, the approach we take is more generally applicable. First,
there are numerous other familial cancer syndromes (Lindor et al. 1998). Family history
based scores are being developed for some of these, including the hereditary nonpolyposis
colon cancer (HNPCC) syndrome with its associated disease genes MLH1 and MSH2. An
evaluation of MLH1/MSH2 carrier scores would involve a similar analysis to that presented
here. This isn’t to suggest that the approach is limited to evaluating carrier scores for disease
genes. Indeed, it is applicable in any setting where an event of interest is observed with error
and where, in practice, that event is predicted using one or more quantitative scores.
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